Hologic’s Multiplex COVID-19/Flu Test became commercially available in North America and Europe

, , , ,

On Oct. 27, 2021, Hologic announced the commercial availability of its Aptima SARS-CoV-2/Flu test in North America and Europe.

The new multiplex Covid-19/Flu test is designed to simultaneously detect and differentiate between three respiratory viruses, namely SARS-CoV-2, influenza A and influenza B.

These three viruses cause similar symptoms, which can include headache, fatigue, cough and fever.

The Aptima SARS-CoV-2/Flu assay can detect and differentiate the viruses by using the company’s real-time transcription-mediated amplification (TMA) technology.

It uses nasopharyngeal and nasal swab samples, which can be collected from individuals with symptoms of respiratory infections or who meet Covid-19 clinical and epidemiological criteria.

The assay has obtained Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) and is authorised under Health Canada’s Interim Order. It is also CE-marked for diagnostic use in Europe.

It runs on Hologic’s Panther molecular diagnostics system, which is completely automated, delivers first results in about three hours and has the capability to process more than 1,000 tests in 24 hours.

Tags:


Source: Medical Device Network
Credit:

LifeScienceHistory.com offers three advertising package options. Each package lnclude at least two digital images for multiple page placements and maximum exposure! Rates range from just $300 to $500 per month.